HeartBeam (NASDAQ: BEAT) announced a strategic reorganization aimed at accelerating execution, expanding global market reach and improving capital efficiency as it advances commercialization of its cardiac monitoring technology. Under the new structure, Founder and President Branislav Vajdic, Ph.D., and Executive Chairman Rich Ferrari will lead focused implementation teams designed to streamline decision-making, improve accountability and reduce costs. As part of the transition, former CEO Robert Eno will move into a consulting role.
The company said its strategy centers on leveraging its patented 3D ECG platform across multiple healthcare channels while advancing development beyond arrhythmia assessment toward heart attack detection. HeartBeam also plans to expand partnerships with governments, health systems, ECG manufacturers and wearable device companies, building on its December 2025 FDA clearance for its synthesized 12-lead ECG technology for arrhythmia assessment.
To view the full press release, visit https://ibn.fm/CTxXi
Questions around this news
What leadership changes did HeartBeam announce?
The company said Founder and President Branislav Vajdic and Executive Chairman Rich Ferrari will lead focused implementation teams under the new structure. Former CEO Robert Eno will take on a consulting role. HeartBeam describes the reorganization as a way to support execution, accountability and cost efficiency as it works to advance commercialization.
What does FDA clearance mean for a medical device?
FDA clearance is a regulatory decision that allows a medical device to be marketed in the United States for a specified intended use. It is distinct from FDA approval, which applies to certain other regulatory pathways. Clearance does not mean a device can be promoted for uses beyond the scope of its cleared indication.
What is a synthesized 12-lead ECG?
An ECG records the heart’s electrical activity. A 12-lead ECG presents that activity from multiple viewpoints to help clinicians assess the heart. A synthesized version uses signals captured by a device and processing methods to derive the views, rather than collecting each view through the conventional arrangement of electrodes.
About HeartBeam, Inc.
HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025(1) . The Company holds over 20 issued patents related to technology enablement.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
At a glance
- Company
- HeartBeam, Inc.
- Ticker
- NASDAQ: BEAT
- Announcement
- Executive
Key figures
- Issued patents
- over 20
- ECG synthesis
- 12-lead
People
- Branislav Vajdic, Ph.D.Founder and President
- Rich FerrariExecutive Chairman
- Robert EnoFormer CEO; moving to a consulting role
Products and programs
SEC filings
Earlier from HeartBeam, Inc.
- HeartBeam (NASDAQ: BEAT) Launches Study Focused on Testing Proprietary Patch Capable of Generating On-Demand 12-Lead ECG for Ischemia Detection
- HeartBeam (NASDAQ: BEAT) Study Shows Portable ECG Device Can Help Identify Heart Attack Risk
- HeartBeam (NASDAQ: BEAT) Advances Commercial Launch, Reports First-Quarter 2026 Results
- HeartBeam (NASDAQ: BEAT) Launches Pilot Study for On-Demand 12-Lead ECG Patch in Coronary Artery Disease Patients
- HeartBeam (NASDAQ: BEAT) to Host Q1 2026 Earnings Call and Provide Strategic Updates
